TY - JOUR T1 - NeoScore integrates characteristics of the neoantigen:MHC class I interaction and expression to accurately prioritize immunogenic neoantigens JF - medRxiv DO - 10.1101/2021.06.24.21259393 SP - 2021.06.24.21259393 AU - Elizabeth S. Borden AU - Kenneth H. Buetow AU - Bonnie J. LaFleur AU - Melissa A. Wilson AU - Karen Taraszka Hastings Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/27/2021.06.24.21259393.abstract N2 - Accurate prioritization of immunogenic neoantigens is key to developing personalized cancer vaccines and distinguishing those patients likely to respond to immune checkpoint inhibition. However, there is no consensus regarding which characteristics best predict neoantigen immunogenicity, and no model to date has both high sensitivity and specificity and a significant association with survival in response to immunotherapy. We address these challenges in the prioritization of immunogenic neoantigens by 1) identifying which neoantigen characteristics best predict immunogenicity, 2) integrating these characteristics into an immunogenicity score, NeoScore, and 3) demonstrating an improved association of the NeoScore with response to immune checkpoint inhibition compared to mutational burden. One thousand random and evenly split combinations of immunogenic and non-immunogenic neoantigens from a validated dataset were analyzed using a regularized regression model for characteristic selection. The selected characteristics, the dissociation constant and binding stability of the neoantigen:MHC class I complex and expression of the mutated gene in the tumor, were integrated into the NeoScore. A web application is provided for calculation of the NeoScore. The NeoScore results in improved, or equivalent, performance in four test datasets as measured by sensitivity, specificity, and area under the receiver operator characteristics curve compared to previous models. Among cutaneous melanoma patients treated with immune checkpoint inhibition, a high NeoScore had a greater association with improved survival compared to mutational burden. Overall, the NeoScore has the potential to improve neoantigen prioritization for the development of personalized vaccines and contribute to the determination of which patients are likely to respond to immunotherapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Springboard Initiative from the University of Arizona College of Medicine-Phoenix (K.T.H), and the University of Arizona College of Medicine-Phoenix M.D./Ph.D. Program (E.S.B).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWES and RNAseq data for the TESLA consortium dataset are available through Synapse. Validation data for the TESLA consortium data is available through the supplementary material from the Wells et al. manuscript. All tested neoantigens, expression data, and validation information for the test datasets are provided through supplementary data tables from their respective publications. RNAseq data for the Cohen dataset was obtained through the NCBI with accession number SRP062169. WES and RNAseq data for both the Liu and Van Allen datasets are accessible through dbgap with the accession number phs000452. Links to all datasets are provided below. https://www.synapse.org/#!Synapse:syn21048999/wiki/603788 https://ars.els-cdn.com/content/image/1-s2.0-S0092867420311569-mmc4.xlsx https://trace.ddbj.nig.ac.jp/DRASearch/study?acc=SRP062169 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607110/bin/JCI82416sdt2.xls https://science.sciencemag.org/highwire/filestream/679287/field_highwire_adjunct_files/2/aaf2288-Table-S8.xlsx https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549796/bin/NIHMS713231-supplement-Tables_S1-S3.xlsx https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577644/bin/NIHMS892660-supplement-Supp_4.pdf https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000452.v3.p1 ER -